Attributable mortality of vancomycin resistance in ampicillin-resistant *Enterococcus faecium* bacteremia in Denmark and the Netherlands: a matched cohort study

Wouter C. Rottier¹, Mette Pinholt^{3,4*}, Akke K. van der Bij^{5,a*}, Magnus Arpi⁶, Sybrandus N. Blank⁷,
Marrigje H. Nabuurs-Franssen⁸, Gijs J.H.M. Ruijs⁹, Matthijs Tersmette¹⁰, Jacobus M. Ossewaarde¹¹,
Rolf H. Groenwold¹², Henrik Westh^{3,4} and Marc J.M. Bonten^{1,2}, on behalf of the Dutch VRE
Bacteremia Investigators and the Danish Collaborative Bacteraemia Network (DACOBAN)

¹Julius Center for Health Sciences and Primary Care, and ²Department of Medical Microbiology, University
Medical Center Utrecht, Utrecht, the Netherlands

³Department of Clinical Microbiology, Hvidovre University Hospital, Hvidovre, Denmark

⁴Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

⁵Centre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment
(RIVM), Bilthoven, the Netherlands

⁶Department of Clinical Microbiology, Herlev University Hospital, Herlev, Denmark

⁷Department of Internal Medicine, Maxima Medical Center, Eindhoven/Veldhoven, the Netherlands

⁸Department of Medical Microbiology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands

⁹Laboratory for Clinical Microbiology and Infectious Diseases, Isala, Zwolle, the Netherlands

¹⁰Department of Medical Microbiology and Immunology, St. Antonius Hospital, Utrecht/Nieuwegein;

¹¹Department of Medical Microbiology, Maasstad Ziekenhuis, Rotterdam, The Netherlands

¹²Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

^a Present affiliation: Department of Medical Microbiology and Immunology, Diaconessenhuis, Utrecht, the
Netherlands.

* Authors contributed equally.

Corresponding author:

Wouter C. Rottier

Julius Center for Health Sciences and Primary Care

University Medical Center Utrecht

Huispostnummer STR 6.131

Postbus 85500

3508 GA Utrecht

the Netherlands.

Telephone: +31 88 75 576 76

Fax: +31 88 75 680 99

E-mail: w.c.rottier-2@umcutrecht.nl

Abstract

Background In many European hospitals, ampicillin-resistant *Enterococcus faecium* (ARE) is endemic, while outbreaks of vancomycin-resistant *E. faecium* (VRE), belonging to the same genetic lineage, are increasingly reported. We studied the attributable mortality due to vancomycin resistance in patients with *E. faecium* bacteremia and evaluated whether this is mediated by a delay in appropriate antibiotic therapy.

Methods In a retrospective matched cohort study, patients with VRE bacteremia occurring between 2009 and 2014 in 20 Dutch and Danish hospitals were matched to patients with ARE bacteremia, on hospital, ward, length of hospital stay prior to bacteremia, and age. The risk ratio (RR) for 30-day mortality contrasting VRE with ARE was estimated with further analytic control for confounding factors.

Results In all, 63 VRE and 234 ARE episodes were matched (36 and 130 for the Netherlands and 27 and 104 for Denmark). Crude 30-day mortality was 27% and 38% for ARE in the Netherlands and Denmark, respectively, and 33% and 48% for VRE in the respective countries. The adjusted RR for 30-day mortality for VRE was 1.54 (95% confidence interval (CI) 1.06-2.25). Although appropriate therapy was initiated later for VRE than for ARE bacteremia, this did not appear to mediate the increased mortality risk.

Conclusions Compared to ARE bacteremia, VRE bacteremia was associated with higher 30-day mortality. One explanation for this association would be increased virulence of VRE, although both phenotypes belong to the same well-characterized core genomic lineage. Alternatively, it may be the result of unmeasured confounding.

Introduction

As many other countries, the Netherlands and Denmark have faced increasingly frequent polyclonal hospital outbreaks of *Enterococcus faecium* with combined resistance to ampicillin and vancomycin (VRE) during the past years [1,2]. In these countries, ampicillin-resistant, vancomycin-susceptible *E. faecium* (ARE) has become the dominant hospital phenotype of *E. faecium* in recent decades [2,3]. Since hospital-acquired VRE and ARE are genetically indistinguishable at the core genome level, VRE is assumed to have originated from the omnipresent ARE through acquisition of *vanA* or *vanB* genes [4–7]. In both countries, infection control policies have been implemented to prevent nosocomial transmission of VRE (contact precautions for VRE carriers, supplemented by contact tracing and augmented general hygiene measures in case of outbreaks [8,9]), but not for ARE. Failure to control VRE transmission will most likely result in VRE endemicity, because the nosocomial ARE populations will in part be supplanted by VRE [3,10].

Controlling VRE outbreaks imposes a great burden on finances and hospital personnel [11]. To make an appropriate cost-benefit analysis of containing VRE spread in a healthcare system, it is essential to quantify the benefits of such a strategy. The most important threat for individual patients is the adversity patients will experience due to VRE infection as compared to ARE infection. A meta-analysis reported increased mortality after VRE bacteremia compared to ARE bacteremia [12], but most studies included had been performed before effective antibiotics for VRE were available. Since then, few have attempted to quantify the effects of VRE infection compared to ARE infection, and those available often suffered from methodological drawbacks,

such as combining *E. faecium* and *Enterococcus faecalis* infection and incomplete control for confounding [13].

We, therefore, sought to investigate the fraction of mortality in VRE bacteremia superimposed by vancomycin resistance, in both the Netherlands and Denmark. We also analyzed whether any such increase is the result of a delay in appropriate antibiotic therapy, as this is *a priori* the most likely mediating mechanism.

Methods

Study design, setting and participants

We addressed a causal research question with an observational study in which confounding bias was dealt with in a two-stepped approach. First, by means of matching, patients with ARE bacteremia and with underlying disease severity similar to the VRE bacteremia patients were chosen as comparison group. Second, we controlled for remaining imbalances in confounding factors after matching by means of adjustment in multivariable models.

This resulted in a retrospective matched cohort study in which episodes of bacteremia caused by *E. faecium* with co-resistance to ampicillin and vancomycin (designated as VRE) were compared to control episodes of bacteremia caused by *E. faecium* with resistance to ampicillin and susceptibility to vancomycin (designated as ARE). Episodes with ampicillin-susceptible VRE bacteremias were excluded. Depending on the availability, a maximum of 4 ARE bacteremias were matched to each VRE bacteremia, using the variables hospital, hospital ward at bacteremia

onset, age and length of stay prior to bacteremia (see Supplementary Material for a complete description).

No formal sample size calculation was performed, as in both involved countries, VRE bacteremias are rare occurrences, and we had to rely on the willingness of hospitals country-wide to participate. In the Netherlands, VRE bacteremia episodes were identified in 13 hospitals through the national surveillance system ISIS-AR [14], and eleven participated in this study, as did five hospitals not linked to ISIS-AR (see Supplementary Table 1 for details of participating hospitals). In Denmark, the DACOBAN database was used to identify patients with VRE bacteremia. DACOBAN is a registry of all positive blood cultures from 10 of 11 hospitals in the Capital Region of Denmark (the exception being the tertiary referral center Rigshospitalet) [15]. Patients with VRE bacteremia were identified in five hospitals of which four participated in this study.

In the Netherlands, we included patients with VRE bacteremia that occurred between 1 January 2009 and 1 January 2013, with deviations in some hospitals (Supplementary Table 1). In Denmark, we included patients with VRE bacteremia that occurred between 1 January 2012 and 1 January 2015.

Minimum inhibitory concentrations (MICs) for ampicillin and vancomycin were used as reported by local laboratories. All Danish laboratories interpreted antimicrobial susceptibility according to EUCAST standards, but most Dutch laboratories switched from CLSI to EUCAST standards in recent years [14]. Vancomycin resistance had to be confirmed by E-test or demonstration of the presence of *vanA* or *vanB*. The specific VRE genotype was based on PCR-testing or on

teicoplanin susceptibility (resistant categorized as *vanA*, susceptible as *vanB*) if PCR testing had not been performed.

The Institutional Review Board of the coordinating center judged the study to be exempt from the Dutch Medical Research Involving Human Subjects Law due to its retrospective nature. Informed consent was not necessary, as data were provided anonymized by treating physicians. In all participating study sites, local regulations for such studies were followed. In Denmark, the study was approved by the Danish Data Protection Agency (registered under 2012-58-0004) and the Danish Health and Medicines Authority (registered under 3-3013-1118/1).

Data collection

After selection of cases and controls, charts were manually reviewed with the date of the index blood culture (bacteremia onset) as reference date. A description of the potential confounding variables and infection-related variables for which data were collected is provided in the Supplementary Material.

Additionally, antibiotic use was registered from 30 days prior to bacteremia onset until 14 days after onset, including type of antibiotic, route of administration, and starting and stopping dates. Antibiotic use prior to bacteremia was considered a potential confounder, whereas treatment provided for the *E. faecium* bacteremia episode was considered the main intermediate variable on the causal pathway leading from vancomycin resistance to increased mortality. To analyze this variable, on each calendar day from bacteremia onset onwards (considered day 0), antibiotic treatment was categorized as (a) either *E. faecium*-covering (i.e. including vancomycin, linezolid, daptomycin, teicoplanin, quinupristin/dalfopristin and/or tigecyclin, regardless of vancomycin

resistance phenotype) or not, and (b) appropriate (i.e. all of the aforementioned antibiotics for ARE infection, all except vancomycin for *vanB* VRE infection, and all except vancomycin and teicoplanin for *vanA* VRE infection) or inappropriate.

The primary outcome of the study was mortality within 30 days of bacteremia onset, and secondary outcomes were mortality within 1 year, in-hospital mortality, length of hospital stay after bacteremia onset, and intensive care unit admission within 7 days of bacteremia onset. For all bacteremia cases, follow-up data (censoring date or date of death) for at least 30 days after bacteremia onset, but preferably up to 1 year after bacteremia onset were collected.

Statistical analysis

The relation between ARE/VRE and 30-day mortality was estimated using Cox regression models, unadjusted as well as adjusted for potential confounding variables. All models were Cox proportional hazards models, with stratification on matched sets, robust standard errors, and correlation between individuals that were included multiple times. For models without censoring, all episodes were given the same arbitrary follow-up time and the Efron approximation for tied survival times was used, so that hazard ratios (HR) could be interpreted as risk ratios (RR) [16]. The standard adjusted models involved inclusion of all potential confounders a priori deemed relevant by us to achieve optimal correction, followed by removal of redundant variables to increase precision [17]. As a sensitivity analysis, stepwise addition and removal of potential confounders was performed, starting from a model including only the exposure of interest. In the Supplementary Material, exact procedures are described. In case of missing values for the variables included in a model, individuals were excluded from the analysis.

Several additional models were created to evaluate mediation of the effect of VRE on mortality through appropriateness of therapy. For this, an interaction between vancomycin resistance and appropriateness of therapy was included. As appropriateness of therapy is a time-varying variable, three models were created in which the baseline was moved to the end of day 0 (day of the index blood culture), +1, and +2, respectively. Patients having died or censored before or on the day of the baseline were removed from the analysis. Appropriateness of therapy in each model reflected the state at baseline.

All statistical analyses were performed in R (version 3.6.1) [18], with the use of packages *survival* [19], *cmprsk* [20], *rms* [21], *mice* [22] and *xtable* [23].

Results

Patient characteristics

In all, 63 VRE episodes were matched to 234 ARE episodes (36 and 130 for the Netherlands, and 27 and 104 for Denmark). VRE and matched ARE bacteremia episodes had largely similar characteristics (Table 1 and Supplementary Table 2). Differences between both countries were also present, most prominently involving treatment restriction prior to bacteremia. The latter variable is generally registered on a dedicated location in Dutch health records, but had to be abstracted from written notes in Denmark. Also, comorbidities were retrieved from the DACOBAN registry in Denmark, whereas they were abstracted from medical notes in the Netherlands.

Most VRE were *vanA* (n = 41, 65%), 19 were *vanB* (30%), one isolate carried both *vanA* and *vanB* and two isolates could not be categorized. All VRE isolates from Denmark (n = 27) were *vanA*. Seventeen isolates were categorized based on teicoplanin susceptibility (3 *vanA* and 14 *vanB*, all from the Netherlands).

Mortality

All patients could be assessed for 30-day mortality, and 76% of censored patients had a follow-up time of at least one year. Crude 30-day mortality was 40% for VRE and 32% for ARE: 33% and 27% for VRE and ARE, respectively, in the Netherlands and 48% and 38% in Denmark. In the Netherlands, 30-day mortality per VRE phenotype was 29% for *vanA* and 37% for *vanB*. The unadjusted RR for 30-day mortality of VRE (compared to ARE) was 1.27 (95% confidence interval (CI) 0.87-1.84; 1.16 (95% CI 0.65-2.06) for the Netherlands, 1.37 (95% CI 0.84-2.25) for Denmark; Table 2). Adjustment for confounding increased the RR to 1.54 (95% CI 1.06-2.25). Within the Dutch subgroup, addition of the confounder *Acute Physiology Score before bacteremia onset* to an otherwise optimally adjusted model reduced the RR of vancomycin resistance from 1.62 to 1.17 (see Supplementary Material).

One year mortality was larger among Danish patients with VRE compared to patients with ARE bacteremia or Dutch patients with VRE or ARE bacteremia (Figure 1). In the multivariable Cox model for mortality up to one year, the HR for VRE amounted to 1.25 (95% CI 0.80-1.98; Table 3).

Antibiotic therapy

Visual inspection of cumulative incidence plots revealed that initiation of *E. faecium*-covering antibiotic therapy occurred faster in VRE than in ARE episodes (Figure 2), but that initiation of appropriate antibiotic therapy occurred faster for ARE compared to VRE bacteremia (Figure 3). In Denmark, appropriate antibiotic therapy for both ARE and VRE bacteremia was started earlier than in the Netherlands, and often consisted of linezolid daptomycin combination treatment (Table 4).

Inclusion of inappropriate antibiotic therapy on the day of the index blood culture (day 0), in itself associated with mortality (RR 2.79 (95% CI 0.99-7.86)), did not alter the effect of VRE on 30 day mortality (Table 2). In models with an interaction between vancomycin resistance and appropriateness of therapy, VRE patients on inappropriate therapy increasingly fared worse over time compared to ARE patients on inappropriate therapy (Table 5). ARE patients on appropriate therapy had better survival than those on inappropriate therapy, but this protective effect seemed to diminish over time. The effect estimates for VRE patients on appropriate therapy were uncertain.

Discussion

This study reveals that, after matching and further analytic control for confounders, VRE bacteremia was, compared to ARE bacteremia, associated with 54% higher risk for mortality after 30 days (RR 1.54, 95% CI 1.06-2.25). Yet, this increased risk of death must be explained by other factors than a delay in appropriate antibiotic therapy.

Our estimate for the effect of VRE on mortality is similar to the reported pooled OR of 2.52 (95% CI 1.9-3.4) in a meta-analysis from 2005 [12], which translates to a RR of 1.70 in case of 32% death rate in the non-exposed group [24]. This seems remarkably identical, as the studies included in that meta-analysis had been performed before the availability of effective antibiotics for VRE, such as linezolid and daptomycin. Yet, a small study comparing older and newer antibiotics in 113 VRE bacteremias concluded that newer antibiotics had not brought discernable benefits to patient outcome [25]. A later meta-analysis on the effect of VRE on mortality in the era of effective antibiotic therapy could only present an unadjusted estimate, and hence cannot be compared to our study [13]. Recent Australian and German studies all found point estimates reflecting increased mortality in case of vancomycin resistance, with confidence intervals indicating non-significance [26–28]. By analyzing the *E. faecium* bacteremia subset and not including intermediate variables in the adjusted model, the OR of 1.283 (95% CI 0.801-2.057) from Kramer *et al.* most closely reflects our estimation procedure [27].

There are three causal pathways along which vancomycin resistance could lead to increased mortality: (i) increased virulence of VRE compared to ARE, (ii) less effective antibiotics for VRE than for ARE, and (iii) a delay in initiation of appropriate antibiotic therapy for VRE bacteremia. We cannot fully exclude a systematic difference in pathogenicity between ARE and VRE, as for example Bender *et al.* have shown that acquisition of *vanB* by *E. faecium* is accompanied by the transfer of larger genetic fragments [29]. However, most studies conclude that both phenotypes belong to the same, well-characterized, core genomic lineage of *E. faecium* [4,7]. Furthermore, to the best of our knowledge, there is no evidence that the appropriate antibiotic options for *E. faecium*, most prominently vancomycin, linezolid or daptomycin, have different efficacy for

susceptible strains. In this study, vancomycin was mostly used for ARE, and linezolid and daptomycin for VRE.

The observed increased mortality in case of VRE bacteremia, therefore, could be expected to result from a delay in appropriate therapy, which has been implicated previously in worse outcomes in case of enterococcal bacteremia [30]. However, our models that include appropriateness of therapy do not offer support for this hypothesis. VRE patients on inappropriate therapy continuously fare worse than ARE patients on inappropriate therapy. Therapy over time may be reflective of the evolving disease severity of the patient, and collider bias may be induced by conditioning on appropriateness of therapy [31]. This means that effect estimates of appropriateness of therapy after baseline may not reflect true causal associations. However, seeing that this trend is discernable from the day of the index blood culture onwards increases our confidence that the difference in duration until appropriate therapy is unable to explain the increased mortality in case of VRE bacteremia. A final indication for this stems from the comparison between countries in this study. Overall mortality in Denmark for both ARE and VRE bacteremia is higher than in Netherlands, although appropriate therapy for both types of bacteremia is initiated considerably faster in Denmark than in the Netherlands.

As these biologically plausible mediators cannot explain increased mortality due to vancomycin resistance, the possibility remains that these observed effects are due to unmeasured confounding. This possibility is supported by two additional observations. First, a measure for clinical disease severity immediately before bacteremia onset was not available for the Danish patients. For the Dutch patients, we could calculate the Acute Physiology score, and when

included in our country-specific analyses, it substantially reduced the effect estimate for mortality (see Supplementary Material). Second, the association between vancomycin resistance and mortality persisted over the course of a full year. Infections may have long-term sequelae [32], but it seems unlikely that sustained mortality differences will emerge that can be causally related to vancomycin resistance. A Dutch population-based study reported that the incidence of recurrent bacteremia, an example of a long-term consequence, only marginally differed between ARE and VRE bacteremia [33]. An alternative explanation is that underlying prognostic factors at the time of onset of enterococcal bacteremia were dissimilar.

Several limitations of this study should be discussed. First, results of this study may not apply to *E. faecium* bacteremia in general, as a non-random subset of ARE bacteremias was included. The matched design does not allow for direct comparisons of raw proportions other than for VRE vs. ARE. Second, some loss in precision may be expected in stratified analyses, as not all matched sets can be used for parameter estimation. Third, measurements of comorbidities and treatment restrictions differed between both countries, whereas these differences were not included in models. Fourth, duration until initiation of appropriate therapy could not be reliably measured in hours, and was reflected instead by calendar days.

Finally, some studies suggest that the incidence of infections with VRE occur on top of the existing incidence of infections caused by vancomycin-susceptible enterococci [34,35]. In that case, a comparison between VRE bacteremia and an uninfected control group would be more appropriate, as described by Chiang *et al.* [36]. Yet, it is important to note that these incidence rates may have been confounded by the fact that *E. faecalis* was not separated from *E. faecium*,

and that results from molecular epidemiological studies provided strong evidence that ARE and VRE occupy the same niche within the bacterial hospital ecology [4].

In conclusion, VRE bacteremia was, when compared to ARE bacteremia, associated with higher mortality. This could not be explained by delays in initiation of appropriate antibiotic therapy, although the relevant models are possibly underpowered and should be interpreted with caution. Because of the large heterogeneity among infected patients and the multiple determinants that mediate the outcome for patients developing *E. faecium* bacteremia, unmeasured confounding is a likely explanation. In that case, replacement of ARE infections by VRE infections would not lead to higher 30-day mortality. The alternative explanation is that VRE is more virulent than ARE. Given the resemblance of the core genomes of ARE and VRE, the genetic basis for hypervirulence would then be most likely encoded in the accessory genome, the mobilome. In that case, emergence of VRE could not only replace ARE infections but also increase the total burden of infection. Further studies are warranted to explore this possibility.

Funding

This work was supported by a research grant from the Netherlands Organisation for Health Research and Development [grant number 205200007] to W.C.R.

Acknowledgment

We would like to thank all participating hospitals for making data collection possible. We specifically thank Marja Smid for her assistance with the data collection in the Netherlands, and Kim Gradel and Steen Rasmussen for extraction of comorbidity data in Denmark. We also thank Rob Willems for critically reviewing an earlier version of this manuscript.

The Dutch VRE Bacteremia Investigators study group consists of: Heidi S.M. Ammerlaan (Catharina Ziekenhuis, Eindhoven), Akke K. van der Bij (National Institute for Public Health and the Environment (RIVM), Bilthoven; present affiliation: Diaconessenhuis, Utrecht), Sybrandus N. Blank (Maxima Medisch Centrum, Eindhoven/Veldhoven), Marc J.M. Bonten (Universitair Medisch Centrum, Utrecht), Els I.G.B. de Brauer (Zuyderland, Heerlen/Sittard-Geleen), Mirjam J.D. Dautzenberg (Universitair Medisch Centrum, Utrecht; present affiliation: Radboudumc, Nijmegen), Laura van Dommelen (Stichting PAMM, Veldhoven), Paul Gruteke (Onze Lieve Vrouwe Gasthuis, Amsterdam; Flevoziekenhuis, Almere), Rogier Jansen (Onze Lieve Vrouwe Gasthuis, Amsterdam), Saskia Kuipers (Radboudumc, Nijmegen), Marringje H. Nabuurs-Franssen (Canisius-Wilhelmina Ziekenhuis, Nijmegen), Lieke Möller (Certe, Groningen), Jacobus M. Ossewaarde (Maasstad Ziekenhuis, Rotterdam), Wouter C. Rottier (Universitair Medisch Centrum,

313 Utrecht), Wouter Rozemeijer (Noordwest Ziekenhuisgroep, Alkmaar), Gijs J.H.M. Ruijs (Isala,
 314 Zwolle), Annelot F. Schoffelen (National Institute for Public Health and the Environment (RIVM),
 315 Bilthoven), Fre W. Sebens (Deventer Ziekenhuis, Deventer; present affiliation: LabMicTA,
 316 Hengelo), Peter M. Schneeberger (Jeroen Bosch Ziekenhuis, 's-Hertogenbosch), Matthijs
 317 Tersmette (St. Antonius Ziekenhuis, Utrecht/Nieuwegein), Saara J. Vainio (VU medisch centrum,
 318 Amsterdam; present affiliation: St. Antonius Ziekenhuis, Utrecht/Nieuwegein), G. Paul Voorn (St.
 319 Antonius Ziekenhuis, Utrecht/Nieuwegein)

320 *The Danish Collaborative Bacteraemia Network (DACOBAN) study group consists of:* Magnus Arpi,
 321 Kim O. Gradel, Ulrich S. Jensen, Jenny D. Knudsen, Kristoffer Koch, Henrik C. Schønheyder, Mette
 322 Søgaaard, Sara Thønnings, Jesper Smit, Mette Pinholt, Christian Ø. Andersen

323 Results from this study were presented at the 25th European Congress of Clinical Microbiology
 324 and Infectious Diseases, Copenhagen, Denmark (25-28 April 2015, oral presentation O090).

325 *Potential conflicts of interest.* All authors: No conflict.

References

1. de Greeff SC, Mouton JW. NethMap 2017: consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands in 2016. Bergen, the Netherlands: Stichting Werkgroep Antibioticabeleid & Rijksinstituut voor Volksgezondheid en Milieu, 2017.
2. Borck Høg B, Korsgaard H, Sönksen UW. DANMAP 2016: use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark. Lyngby & Copenhagen, Denmark: Statens Serum Institut, DTU Veterinærinstituttet & DTU Fødevareinstituttet, 2017.
3. Top J, Willems RJL, Bonten MJM. Emergence of CC17 *Enterococcus faecium*: from commensal to hospital-adapted pathogen. *FEMS Immunol Med Microbiol* **2008**; 52:297–308.
4. Guzman Prieto AM, van Schaik W, Rogers MRC, et al. Global emergence and dissemination of enterococci as nosocomial pathogens: Attack of the clones? *Front Microbiol* **2016**; 7:788.
5. Howden BP, Holt KE, Lam MMC, et al. Genomic insights to control the emergence of vancomycin-resistant enterococci. *MBio* **2013**; 4:e00412-13.
6. Pinholt M, Gumpert H, Bayliss S, et al. Genomic analysis of 495 vancomycin-resistant *Enterococcus faecium* reveals broad dissemination of a vanA plasmid in more than 19 clones from Copenhagen, Denmark. *J Antimicrob Chemother* **2017**; 72:40–47.

- 346 7. Raven KE, Reuter S, Reynolds R, et al. A decade of genomic history for healthcare-
347 associated *Enterococcus faecium* in the United Kingdom and Ireland. *Genome Res* **2016**;
348 26:1388–1396.
- 349 8. Bijzonder resistente micro-organismen (BRMO). Leiden, the Netherlands: Werkgroep
350 Infectiepreventie, 2013.
- 351 9. Nationale infectieshygiejnische retningslinjer om supplerende forholdsregler ved
352 infektioner og bærertilstand i sundhedssektoren (5. udgave). Copenhagen, Denmark:
353 Central Enhed for Infektionshygiejne (Statens Serum Institut), 2016.
- 354 10. Johnstone J, Policarpio ME, Lam F, et al. Rates of blood cultures positive for vancomycin-
355 resistant *Enterococcus* in Ontario: a quasi-experimental study. *CMAJ Open* **2017**; 5:E273–
356 E280.
- 357 11. Dik JWH, Dinkelacker AG, Vemer P, et al. Cost-analysis of seven nosocomial outbreaks in
358 an academic hospital. *PLoS One* **2016**; 11:e0149226.
- 359 12. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated
360 with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream
361 infections: a meta-analysis. *Clin Infect Dis* **2005**; 41:327–33.
- 362 13. Prematunge C, MacDougall C, Johnstone J, et al. VRE and VSE bacteremia outcomes in
363 the era of effective VRE therapy: a systematic review and meta-analysis. *Infect Control*
364 *Hosp Epidemiol* **2016**; 37:26–35.
- 365 14. Altorf-van der Kuil W, Schoffelen AF, de Greeff SC, et al. National laboratory-based

366 surveillance system for antimicrobial resistance: a successful tool to support the control of
367 antimicrobial resistance in the Netherlands. Euro Surveill **2017**; 22:pil=17-00062.

368 15. Gradel KO, Schønheyder HC, Arpi M, Knudsen JD, Østergaard C, Sogaard M. The Danish
369 Collaborative Bacteraemia Network (DACOBAN) database. Clin Epidemiol **2014**; 6:301–
370 308.

371 16. Cummings P. Re: 'Estimating the relative risk in cohort studies and clinical trials of
372 common outcomes'. Am J Epidemiol **2004**; 159:213.

373 17. Greenland S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology:
374 traditional methods and basic alternatives. Int J Epidemiol **2016**; 45:565–575.

375 18. R Core Team. R: A language and environment for statistical computing. Vienna, Austria:
376 2020.

377 19. Therneau T. A package for survival analysis in R (R package version 3.1-11). 2020;

378 20. Gray B. cmprsk: subdistribution analysis of competing risks (R package version 2.2-9).
379 2019;

380 21. Harrell Jr FE. rms: Regression Modeling Strategies (R package version 5.1-4). 2019;

381 22. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained
382 equations in R. J Stat Softw **2011**; 45.

383 23. Dahl DB, Scott D, Roosen C, Magnusson A, Swinton J. xtable: export tables to LaTeX or
384 HTML (R package version 1.8-4). 2019;

- 385 24. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort
386 studies of common outcomes. JAMA **1998**; 280:1690–1.
- 387 25. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics
388 quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-
389 resistant Enterococcus bacteremia. Clin Infect Dis **2008**; 46:30–6.
- 390 26. Cheah ALY, Spelman T, Liew D, et al. Enterococcal bacteraemia: factors influencing
391 mortality, length of stay and costs of hospitalization. Clin Microbiol Infect **2013**; 19:E181–
392 E189.
- 393 27. Kramer TS, Remschmidt C, Werner S, et al. The importance of adjusting for enterococcus
394 species when assessing the burden of vancomycin resistance: a cohort study including
395 over 1000 cases of enterococcal bloodstream infections. Antimicrob Resist Infect Control
396 **2018**; 7:133.
- 397 28. Dubler S, Lenz M, Zimmermann S, et al. Does vancomycin resistance increase mortality in
398 Enterococcus faecium bacteraemia after orthotopic liver transplantation? A retrospective
399 study. Antimicrob Resist Infect Control **2020**; 9:22.
- 400 29. Bender JK, Kalmbach A, Fleige C, Klare I, Fuchs S, Werner G. Population structure and
401 acquisition of the vanB resistance determinant in German clinical isolates of Enterococcus
402 faecium ST192. Sci Rep **2016**; 6:21847.
- 403 30. Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact
404 of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal

bloodstream infections. Clin Infect Dis **2016**; 62:1242–1250.

31. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology **2004**; 15:615–25.

32. Leibovici L. Long-term consequences of severe infections. Clin Microbiol Infect **2013**; 19:510–512.

33. Woudt SHS, de Greeff SC, Schoffelen AF, Vlek ALM, Bonten MJM, Infectious Diseases Surveillance Information System–Antimicrobial Resistance (ISIS-AR) Study Group. Antibiotic resistance and the risk of recurrent bacteremia. Clin Infect Dis **2018**; 66:1651–1657.

34. Ammerlaan HSM, Harbarth S, Buiting AGM, et al. Secular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infection. Clin Infect Dis **2013**; 56:798–805.

35. Popiel KY, Miller MA. Evaluation of vancomycin-resistant enterococci (VRE)-associated morbidity following relaxation of VRE screening and isolation precautions in a tertiary care hospital. Infect Control Hosp Epidemiol **2014**; 35:818–25.

36. Chiang H-Y, Perencevich EN, Nair R, et al. Incidence and outcomes associated with infections caused by vancomycin-resistant enterococci in the United States: systematic literature review and meta-analysis. Infect Control Hosp Epidemiol **2017**; 38:203–215.

Table 1. Characteristics and outcomes of VRE and matched ARE bacteremias

	Netherlands		Denmark	
	ARE bacteremia, n/N with data (%)	VRE bacteremia, n/N with data (%)	ARE bacteremia, n/N with data (%)	VRE bacteremia, n/N with data (%)
Potential confounding variables				
Female	47/130 (36)	19/36 (53)	51/104 (49)	10/27 (37)
Age, median (IQR)	70 (62-76)	69 (62-76)	69 (63-77)	71 (58-76)
Hospital ward at bacteremia onset				
- Internal medicine	47/130 (36)	15/36 (42)	31/104 (30)	8/27 (30)
- ICU	48/130 (37)	11/36 (31)	25/104 (24)	6/27 (22)
- Gastro-enterology/surgery	34/130 (26)	9/36 (25)	31/104 (30)	8/27 (30)
- Other	1/130 (1)	1/36 (3)	17/104 (16)	5/27 (19)
Bacteremia origin				
- Hospital-onset	113/130 (87)	29/36 (81)	93/104 (89)	24/27 (89)
- Healthcare-associated	15/130 (12)	4/36 (11)	10/104 (10)	1/27 (4)
- Community-onset	2/130 (2)	3/36 (8)	1/104 (1)	1/27 (4)
Length of hospital stay prior to bacteremia, median (IQR)	17 (11-24)	20 (14-36)	18 (6-24)	21 (10-29)
Preceding hospital admission within 3 months prior to bacteremia	58/130 (45)	15/36 (42)	47/103 (46)	13/26 (50)
Charlson index, median (IQR)	2 (2-3)	2 (1-4)	3 (1-4)	3 (2-6)
Hematological malignancy - under treatment	31/130 (24)	10/36 (28)	9/104 (9)	6/27 (22)
Metastasized solid malignancy	13/130 (10)	1/36 (3)	13/104 (12)	6/27 (22)
Neutropenia at bacteremia onset	32/130 (25)	11/36 (31)	8/104 (8)	6/27 (22)

Treatment restriction in place at bacteremia onset	26/130 (20)	10/36 (28)	5/102 (5)	2/27 (7)
Surgical procedure within 30 days prior to bacteremia	46/130 (35)	9/36 (25)	33/103 (32)	12/27 (44)
Known colonization with <i>E. faecium</i>				
- No	90/130 (69)	18/36 (50)	88/104 (85)	16/27 (59)
- Yes: ARE	38/130 (29)	7/36 (19)	16/104 (15)	2/27 (7)
- Yes: VRE	2/130 (2)	11/36 (31)	0/104 (0)	9/27 (33)
Antibiotic use within 30 days prior to bacteremia	122/130 (94)	33/36 (92)	95/104 (91)	25/27 (93)
Vancomycin use within 30 days prior to bacteremia	13/130 (10)	15/36 (42)	9/104 (9)	6/27 (22)
Infection-related variables				
Polymicrobial bacteremia	35/130 (27)	8/36 (22)	31/103 (30)	11/27 (41)
Severe sepsis at bacteremia onset	30/129 (23)	10/36 (28)	20/104 (19)	4/27 (15)
Bacteremia source				
- Primary bacteremia/central line infection/not identifiable from medical file	60/130 (46)	19/36 (53)	59/104 (57)	11/27 (41)
- Biliary tract infection	15/130 (12)	4/36 (11)	10/104 (10)	2/27 (7)
- Other intra-abdominal infection	35/130 (27)	9/36 (25)	12/104 (12)	7/27 (26)
- Other	20/130 (15)	4/36 (11)	23/104 (22)	7/27 (26)
Source control performed before day +7 ^a (if applicable to source)	38/79 (48)	8/19 (42)	25/47 (53)	4/13 (31)
Outcome variables				
ICU admission before day +7 ^a (if not yet in ICU)	4/82 (5)	4/25 (16)	9/79 (11)	1/21 (5)
Length of hospital stay after bacteremia onset (median, IQR)	22 (10-38)	13 (8-24)	16 (8-36)	14 (6-30)
In-hospital mortality	34/130 (26)	10/36 (28)	38/104 (37)	16/27 (59)
Mortality before day +30 ^a	35/130 (27)	12/36 (33)	40/104 (38)	13/27 (48)

This table presents a selection of recorded variables. A full overview is available in Supplementary Table 2.

Abbreviations: ICU, intensive care unit; IQR, interquartile range.

^a Day 0 is the day of the index blood culture of the ARE/VRE bacteremia episode.

Table 2. Regression models for 30-day mortality

	Unadjusted models			Combined adjusted models		
	Combined	Netherlands	Denmark	Main analysis	Sensitivity analysis	Therapy added
<i>No of observations</i>	297	166	131	297	295	297
<i>No of events</i>	100	47	53	100	99	100
<i>No of variables</i>	1	1	1	5	8	6
<i>Events to variables</i>	100	47	53	20	12.4	16.7
Vancomycin resistance	1.27 (0.87-1.84)	1.16 (0.65-2.06)	1.37 (0.84-2.25)	1.54 (1.06-2.25)	1.49 (0.99-2.22)	1.55 (1.07-2.26)
Inappropriate therapy on day of index blood culture						2.79 (0.99-7.86)

This table presents risk ratios (RR, with 95% CI) for 30-day mortality for the exposure of interest (*vancomycin resistance*), with and without adjustment for confounding variables, and with and without the intermediate variable *inappropriate therapy on day of index blood culture*. In the Supplementary Material, the adjustment procedure is described. Combined models include data from both the Netherlands and Denmark.

Table 3. Regression models for one-year follow-up for mortality

	Unadjusted models			Combined adjusted models	
	Combined	Netherlands	Denmark	Main analysis	Sensitivity analysis
<i>No of observations</i>	297	166	131	294	297
<i>No of events</i>	170	90	80	170	170
<i>No of variables</i>	1	1	1	12	7
<i>Events to variables</i>	170	90	80	14.2	24.3
Vancomycin resistance	1.18 (0.84-1.65)	0.91 (0.53-1.55)	1.51 (0.97-2.36)	1.25 (0.80-1.98)	1.46 (0.95-2.25)

This table presents hazard ratios (HR, with 95% CI) for mortality (follow-up of 1 year with censoring) for the exposure of interest (*vancomycin resistance*), with and without adjustment for confounding variables. In the Supplementary Material, the adjustment procedure is described. Combined models include data from both the Netherlands and Denmark.

Table 4. Overview of antibiotic therapy for VRE and matched ARE bacteremias

	End of day 0 ^a				End of day +3 ^a			
	ARE		VRE		ARE		VRE	
	NL, n/N with data (%)	DK, n/N with data (%)	NL, n/N with data (%)	DK, n/N with data (%)	NL, n/N with data (%)	DK, n/N with data (%)	NL, n/N with data (%)	DK, n/N with data (%)
Deceased	1/130 (1)	2/104 (2)	1/36 (3)	1/27 (4)	12/130 (9)	13/104 (12)	4/36 (11)	4/27 (15)
Censored^b					1/130 (1)			
Discharged	1/130 (1)			1/27 (4)	5/130 (4)	1/104 (1)	1/36 (3)	2/27 (7)
E. faecium-covering therapy	10/129 (8)	5/102 (5)	13/35 (37)	7/26 (27)	76/117 (65)	82/91 (90)	20/32 (62)	22/23 (96)
- vancomycin iv	9/129 (7)	5/102 (5)	12/35 (34)	5/26 (19)	72/117 (62)	79/91 (87)	8/32 (25)	2/23 (9)
- linezolid iv			1/35 (3)	1/26 (4)	1/117 (1)	1/91 (1)	6/32 (19)	7/23 (30)
- daptomycin iv + linezolid iv								10/23 (43)
- teicoplanin iv	1/129 (1)				2/117 (2)		4/32 (12)	
- linezolid po				1/26 (4)			2/32 (6)	2/23 (9)
- daptomycin iv						2/91 (2)		
- vancomycin intrathecally					1/117 (1)			
- linezolid iv + tigecyclin iv								1/23 (4)
Appropriate therapy	10/129 (8)	5/102 (5)	1/35 (3)	2/26 (8)	76/117 (65)	82/91 (90)	12/32 (38)	20/23 (87)
Appropriate therapy or central line removed	12/129 (9)	5/102 (5)	2/35 (6)	2/26 (8)	76/117 (65)	82/91 (90)	12/32 (38)	20/23 (87)

Abbreviations: DK, Denmark; iv, intravenously; NL, Netherlands; po, orally.

^a Day 0 is the day of the index blood culture of the ARE/VRE bacteremia episode.

^b One Dutch patient with ARE bacteremia was censored for the assessment of antibiotic therapy (not for mortality) due to transfer to another hospital.

Table 5. Regression models for 30-day mortality evaluating appropriateness of therapy

	Baseline after day ...		
	0	+1	+2
Unadjusted models			
<i>No of observations</i>	289	283	274
<i>No of events</i>	95	88	80
ARE – on inappropriate therapy	Reference	Reference	Reference
ARE – on appropriate therapy	0.41 (0.10-1.74)	0.82 (0.45-1.51)	1.01 (0.57-1.79)
VRE – on inappropriate therapy	1.24 (0.82-1.85)	1.15 (0.71-1.88)	1.40 (0.73-2.70)
VRE – on appropriate therapy	NA	1.53 (0.68-3.46)	1.32 (0.64-2.71)
Adjusted models – main analysis			
<i>No of observations</i>	289	276	268
<i>No of events</i>	95	87	80
<i>No of variables</i>	9	14	14
<i>Events to variables</i>	10.6	6.2	5.7
ARE – on inappropriate therapy	Reference	Reference	Reference
ARE – on appropriate therapy	0.33 (0.08-1.40)	0.79 (0.43-1.45)	0.82 (0.47-1.43)
VRE – on inappropriate therapy	1.69 (1.09-2.61)	2.01 (1.13-3.57)	2.43 (0.94-6.33)
VRE – on appropriate therapy	NA	5.79 (1.43-23.40)	1.73 (0.83-3.61)
Adjusted models – sensitivity analysis			
<i>No of observations</i>	285	278	270
<i>No of events</i>	94	87	80
<i>No of variables</i>	16	17	15
<i>Events to variables</i>	5.9	5.1	5.3
ARE – on inappropriate therapy	Reference	Reference	Reference
ARE – on appropriate therapy	0.31 (0.08-1.13)	0.69 (0.38-1.28)	0.88 (0.42-1.84)
VRE – on inappropriate therapy	1.42 (0.79-2.55)	1.81 (0.99-3.31)	2.38 (0.99-5.74)
VRE – on appropriate therapy	NA	2.60 (0.55-12.32)	2.12 (0.88-5.09)

This table presents risk ratios (RR, with 95% CI) for 30-day mortality for the interaction between *vancomycin resistance* and *appropriateness of therapy*. The baseline for these models is positioned on three different moments, namely the end of the day of the index blood culture

(day 0), the end of the day after (day +1), and the end of the day thereafter (day +2). This implies that separately for each baseline, patients having died (or censored, as antibiotic therapy could not be fully assessed) before this moment were removed from the dataset.

Appropriateness of therapy refers to the antibiotic therapy provided at baseline. RRs are presented with and without adjustment for confounding variables. In the Supplementary Material, the adjustment procedure is described. All models include data from both the Netherlands and Denmark.

Figure 1. One-year survival curve for VRE and matched ARE bacteremias

Kaplan-Meier plot indicating one-year survival after ARE/VRE bacteremia, stratified on *vancomycin resistance* and *country*.

Abbreviations: NL, Netherlands, DK, Denmark.

Figure 2. Time to *Enterococcus faecium*-covering antibiotic therapy for VRE and matched ARE bacteremias

Cumulative incidence plots of initiation of *E. faecium*-covering antibiotic therapy after onset of bacteremia and its competing risk mortality before onset of *E. faecium*-covering antibiotic therapy, stratified on *vancomycin* resistance.

Abbreviations: Efm Tx, *Enterococcus faecium*-covering therapy.

Figure 3. Time to appropriate antibiotic therapy for VRE and matched ARE bacteremias

Cumulative incidence plots of initiation of appropriate antibiotic therapy after onset of bacteremia and its competing risk mortality before onset of appropriate antibiotic therapy, stratified on *vancomycin resistance*.

Abbreviations: appr Tx, appropriate therapy.